{
  "id": 1775630,
  "title": "Amylyx stock soars after its GLP-1 blocker cut dangerous low-blood-sugar events in trial",
  "url": "https://urgent.news/2026/08/18/amylyx-stock-soars-after-its-glp-1-blocker-cut-dangerous-low-blood",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T18:30:29.000Z",
  "source": {
    "name": "Quartz",
    "slug": "quartz",
    "url": "https://qz.com/amylyx-stock-avexitide-phase-3-trial-pbh-081826"
  },
  "original_language": "en",
  "account": null,
  "summary": "Patients on avexitide experienced 55% fewer severe hypoglycemic events than those on a placebo in the late-stage study",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}